Receive Information

Imugene Ltd (ASX: IMU)

  • Imugene is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.
     
  • HER-Vaxx is a immuno-oncologytherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria. Imugene announced a new partnership to develop mimotope-based immunotherapies against validated and new oncology targets.